Unknown

Dataset Information

0

The TreaT-Assay: A Novel Urine-Derived Donor Kidney Cell-Based Assay for Prediction of Kidney Transplantation Outcome.


ABSTRACT: Donor-reactive immunity plays a major role in rejection after kidney transplantation, but analysis of donor-reactive T-cells is not applied routinely. However, it has been shown that this could help to identify patients at risk of acute rejection. A major obstacle is the limited quantity or quality of the required allogenic stimulator cells, including a limited availability of donor-splenocytes or an insufficient HLA-matching with HLA-bank cells. To overcome these limitations, we developed a novel assay, termed the TreaT (Transplant reactive T-cells)-assay. We cultivated renal tubular epithelial cells from the urine of kidney transplant patients and used them as stimulators for donor-reactive T-cells, which we analyzed by flow cytometry. We could demonstrate that using the TreaT-assay the quantification and characterization of alloreactive T-cells is superior to other stimulators. In a pilot study, the number of pre-transplant alloreactive T-cells negatively correlated with the post-transplant eGFR. Frequencies of pre-transplant CD161+ alloreactive CD4+ T-cells and granzyme B producing alloreactive CD8+ T-cells were substantially higher in patients with early acute rejection compared to patients without complications. In conclusion, we established a novel assay for the assessment of donor-reactive memory T-cells based on kidney cells with the potential to predict early acute rejection and post-transplant eGFR.

SUBMITTER: Thieme CJ 

PROVIDER: S-EPMC6911059 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


Donor-reactive immunity plays a major role in rejection after kidney transplantation, but analysis of donor-reactive T-cells is not applied routinely. However, it has been shown that this could help to identify patients at risk of acute rejection. A major obstacle is the limited quantity or quality of the required allogenic stimulator cells, including a limited availability of donor-splenocytes or an insufficient HLA-matching with HLA-bank cells. To overcome these limitations, we developed a nov  ...[more]

Similar Datasets

| S-EPMC6283554 | biostudies-other
| S-EPMC7186701 | biostudies-literature
| S-EPMC9670834 | biostudies-literature
| S-EPMC9521589 | biostudies-literature
| S-EPMC8509629 | biostudies-literature
| S-EPMC7315672 | biostudies-literature
| S-EPMC9470052 | biostudies-literature
| S-EPMC7190926 | biostudies-literature
| S-EPMC8640566 | biostudies-literature
| S-EPMC6540619 | biostudies-literature